BR112018005771A2 - composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata. - Google Patents

composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata.

Info

Publication number
BR112018005771A2
BR112018005771A2 BR112018005771A BR112018005771A BR112018005771A2 BR 112018005771 A2 BR112018005771 A2 BR 112018005771A2 BR 112018005771 A BR112018005771 A BR 112018005771A BR 112018005771 A BR112018005771 A BR 112018005771A BR 112018005771 A2 BR112018005771 A2 BR 112018005771A2
Authority
BR
Brazil
Prior art keywords
compound
therapeutic
alopecia areata
pharmaceutical composition
preventive agent
Prior art date
Application number
BR112018005771A
Other languages
English (en)
Other versions
BR112018005771B1 (pt
Inventor
Tanimoto Atsuo
Sierra Michael
Labuda Tord
Shinozaki Yuichi
Original Assignee
Japan Tobacco Inc
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Japan Tobacco Inc, Leo Pharma As filed Critical Japan Tobacco Inc
Publication of BR112018005771A2 publication Critical patent/BR112018005771A2/pt
Publication of BR112018005771B1 publication Critical patent/BR112018005771B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção fornece um tratamento inovador de alopecia areate. o problema a ser solucionado pela invenção é fornecer um novo uso farmacêutico de 3-[(3s,4r)-3-metil-6-(7h-pirrolo[2,3-d]pirimidin-4-il)-1,6-diazaspiro[3,4]octan-1-il]-3-oxopropanonitrila. um agente terapêutico ou preventivo para alopecia areata, contendo 3-[(3s,4r)-3-metil-6-(7h-pirrolo[2,3-d]pirimidin-4-il)-1,6-diazaspiro[3.4]octan-1-il]-3-oxopropanonitrila como um ingrediente ativo.
BR112018005771-1A 2015-09-24 2016-09-22 Uso de um composto BR112018005771B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
EP15186644.9 2015-09-24
JP2015-190849 2015-09-29
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (2)

Publication Number Publication Date
BR112018005771A2 true BR112018005771A2 (pt) 2018-10-09
BR112018005771B1 BR112018005771B1 (pt) 2023-12-05

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005771-1A BR112018005771B1 (pt) 2015-09-24 2016-09-22 Uso de um composto

Country Status (27)

Country Link
US (2) US20180263986A1 (pt)
EP (1) EP3352734B1 (pt)
JP (1) JP6776345B2 (pt)
KR (1) KR20180054767A (pt)
CN (1) CN108135834B (pt)
AU (2) AU2016325388A1 (pt)
BR (1) BR112018005771B1 (pt)
CA (1) CA2998972A1 (pt)
CY (1) CY1122837T1 (pt)
DK (1) DK3352734T3 (pt)
ES (1) ES2779762T3 (pt)
HK (1) HK1257770A1 (pt)
HR (1) HRP20200472T1 (pt)
HU (1) HUE049052T2 (pt)
IL (3) IL298520A (pt)
LT (1) LT3352734T (pt)
MX (1) MX2018003332A (pt)
MY (1) MY196541A (pt)
PL (1) PL3352734T3 (pt)
PT (1) PT3352734T (pt)
RS (1) RS60365B1 (pt)
RU (1) RU2754997C2 (pt)
SG (1) SG10202111361TA (pt)
SI (1) SI3352734T1 (pt)
TW (1) TWI720022B (pt)
UA (1) UA124192C2 (pt)
WO (1) WO2017050891A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
TW202406553A (zh) 2022-04-20 2024-02-16 丹麥商理奧藥品公司 前額纖維化禿髮之治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
CY1122837T1 (el) 2021-05-05
CN108135834B (zh) 2021-07-27
US20180263986A1 (en) 2018-09-20
SG10202111361TA (en) 2021-12-30
RU2754997C2 (ru) 2021-09-08
HUE049052T2 (hu) 2020-09-28
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
JP6776345B2 (ja) 2020-10-28
TW201717955A (zh) 2017-06-01
JP2018528238A (ja) 2018-09-27
SI3352734T1 (sl) 2020-07-31
UA124192C2 (uk) 2021-08-04
HRP20200472T1 (hr) 2020-09-18
MY196541A (en) 2023-04-19
KR20180054767A (ko) 2018-05-24
ES2779762T3 (es) 2020-08-19
TWI720022B (zh) 2021-03-01
AU2022202508A1 (en) 2022-05-12
CN108135834A (zh) 2018-06-08
HK1257770A1 (zh) 2019-10-25
EP3352734A1 (en) 2018-08-01
MX2018003332A (es) 2018-08-16
AU2016325388A1 (en) 2018-03-29
CA2998972A1 (en) 2017-03-30
IL257918A (en) 2018-05-31
RU2018114922A3 (pt) 2019-12-11
US20220088020A1 (en) 2022-03-24
EP3352734B1 (en) 2020-01-15
IL298520A (en) 2023-01-01
DK3352734T3 (da) 2020-03-30
LT3352734T (lt) 2020-04-10
BR112018005771B1 (pt) 2023-12-05
RS60365B1 (sr) 2020-07-31
IL312861A (en) 2024-07-01
PL3352734T3 (pl) 2020-08-24
RU2018114922A (ru) 2019-10-28

Similar Documents

Publication Publication Date Title
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CL2016001895A1 (es) Compuestos
EA201992722A1 (ru) N2,n4-дифенилпиримидин-2,4-диаминовое производное, способ его получения и фармацевтическая композиция, содержащая его в качестве активного ингредиента, для профилактики и лечения рака
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016021011A8 (pt) composição tópica e usos de um composto
HK1257615A1 (zh) 用於治療癌症、含有多酚化合物作為活性成分的藥物組合物
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
MX363543B (es) Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo.
CL2018001085A1 (es) Derivados de indolin-2-ona
CL2015002721A1 (es) Formulaciones oftálmicas
PH12017500159A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
BR112018005771A2 (pt) composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
BR112018014769A2 (pt) ?composto, composição farmacêutica, e, método para tratamento do eczema nas mãos?
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
EP3542797A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DYRK-RELATED ILLNESSES USING PYRIDINE-BASED COMPOUNDS AS AN ACTIVE SUBSTANCE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: LEO PHARMA A/S (DK) ; JAPAN TOBACCO INC. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/09/2016, OBSERVADAS AS CONDICOES LEGAIS